[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Gabon\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":172},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,86,112,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100548541","a-rapid-triage-test-to-improve-risk-stratification-of-febrile-children-echilibrist-clinical-trial-1-outpatients-100548541",false,"NCT06422338","A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients)","A Multi-country, Two-arm, Open-label, Superiority, Randomised Controlled Trial to Study the Performance of a Rapid Triage Test Compared to Standard of Care (IMCI-based) to Guide Admission\u002FDischarge Decisions During the First Clinical Assessment of Children With Fever","Inclusion Criteria:\n\n* Age ≥2 months and \\\u003C60 months\n* Written informed consent from the child's parent or caregiver\n* History of fever for ≤7 days OR hypothermia (i.e., axillary temperature \\\u003C35.5ºC) OR suspected severe infection (e.g., in children with moderate or severe acute malnutrition).\n* Lives within the catchment area of the study facility and must intend to continue to reside there for the duration of the study\n* For the RTI sub-study only: presence of respiratory symptoms compatible with RTI.\n\nExclusion Criteria:\n\n* Weight less than 2.5kg\n* Main reason for consultation is an injury, trauma or acute poisoning\n* Enrolled in another clinical trial testing a new drug\n* Enrolled in a vaccine trial in the last 3 months.\n* Any other condition determined by the investigators that makes it unlikely that the participant would complete the study","ALL","2 Months","60 Months",{"count":20,"type":21},5212,"ESTIMATED","INTERVENTIONAL",[24],"NA","The overall aim of the study is to provide evidence that introducing novel biomarkers evaluation at triaging (first clinical assessment), in combination with IMCI-based guidelines (SoC), is a viable strategy to enhance rapid and accurate identification of febrile children at increased risk of life-threatening infections compared to IMCI-based strategies alone (SoC), and to demonstrate whether this results in enhanced decisions of admission\u002Freferral vs discharge, and enhanced overall health outcome of children with acute fever in sub-Saharan Africa.",[27,28,29],"Infectious Disease","Febrile Illness","Child, Only",[31,32,33,34,35],"biomarkers","severity","point-of-care","triage","sub-Saharan Africa","RECRUITING","2026-07-27",{"date":39,"type":40},"2026-07-28","ACTUAL",{"date":42,"type":40},"2025-07-02",{"date":44,"type":21},"2027-08-31",{"name":46,"class":47},"Barcelona Institute for Global Health","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100501295","phase-2-panacea---step2c--01-100501295","NCT05807399","PanACEA - STEP2C -01","A Multiple-arm, Multiple-stage (MAMS), Phase 2B\u002FC, Open-label, Randomized, Controlled Platform Trial to Evaluate Experimental Arms Including Optimised Use of Existing and Introduction of Novel Anti-tuberculosis Drugs, in Adults With Newly Diagnosed, Drug-sensitive, Smear-positive Pulmonary Tuberculosis","Inclusion Criteria:\n\n1. Provide written, informed consent prior to all trial-related procedures including HIV testing.\n2. Male or female, aged between 18 and 65 years, inclusive.\n3. Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.\n4. Newly diagnosed, previously untreated, drug susceptible pulmonary TB: presence of MTB complex and rapid molecular tests result confirming susceptibility to RIF and INH such as GeneXpert and\u002For HAIN MTBDR plus. Participants who had a previous history of TB may be enrolled in this trial, if they:\n\n   * had a good treatment response in the opinion of the investigator; i.e. TB symptoms improved sufficiently or resolved suggesting a cure of the past episode; AND\n   * no persistent microbiological positivity is seen (in case microbiological results are available); AND - their treatment course was completed AND\n   * the last dose of treatment was more than 3 months ago.\n5. A chest X-ray (no older than 2 weeks) which shows abnormalities that, in the opinion of the Investigator, are consistent with TB.\n6. Sputum positive on microscopy from concentrated sputum for acid-fast bacilli (at least 1+ on the IUATLD\u002FWHO scale) AND\u002FOR positive GeneXpert MTB\u002FRIF Ultra® semi-quantitative result \"medium\" or \"high\" on at least one sputum sample.\n7. The participant understands the interaction between the study drugs and certain foods and is willing to forgo the consumption of those foods for the period of study medication.\n8. The participant is not of child-bearing potential or is willing to use effective methods of contraception when engaging in heterosexual intercourse, as defined below:\n\n   1. Non-childbearing potential:\n\n   i. Female participant\u002Fsexual partner of male participant: Bilateral oophorectomy, and\u002For hysterectomy or bilateral tubal ligation more than 12 months ago and\u002For has been postmenopausal with a history of no menses for at least 12 consecutive months and confirmed by a FSH test.\n\n   ii. Male participant\u002Fsexual partner of female participant: Vasectomised or has had a bilateral orchidectomy minimally three months prior to screening iii. Male participants having a pregnant female partner or a male sexual partner: At least one barrier method has to be used in this case.\n\n   b. Effective contraception methods: i. Female participants: Two methods, including methods that the participant's sexual partner(s) use. At least one must be a barrier method. Contraception must be practised for at least until 12 weeks after the last dose of experimental treatment. For stage 3, female participants of child-bearing potential must have used contraception if any sexual intercourse has occurred after last menses or within the last 3 weeks (whichever is later) before participation, and agree to use non-user dependent contraception: depo-provera injection\\* or an intrauterine device additional to one barrier method.\n\n   \\*Including a back-up method of contraception for at least 7 days to prevent unintended pregnancy if injection has been administered within the first 5 days of their menstrual cycle. Otherwise, a back-up barrier method of contraception is required for one month to prevent unintended pregnancy.\n\n   ii. Male participants: Two methods, including methods that the participant's female sexual partner(s) use. At least one must be a barrier method. Effective contraception must be ensured for at least 12 weeks after the last dose of experimental treatment.\n\n   Exclusion Criteria:\n\n\u003C!-- -->\n\n1. Circumstances that raise doubt about free, unconstrained consent to study participation (e.g., person in detention or person with mental disability)\n2. Poor general condition where delay in treatment cannot be tolerated or death within four months is likely.\n3. Circumstances (in the opinion of the investigator) that raise doubt about ability to complete the follow-up during the study period.\n4. The participant is pregnant or breast-feeding or planning to become pregnant in the study period.\n5. The participant is infected with HIV with a CD4 count \\\u003C220 cells\u002Fmm3. If \\>220 cells\u002Fmm3, participants will be included only if any of the following is applicable:\n\n   • The participant is antiretroviral (ARV) naïve and able to postpone commencing HIV treatment for 2 months after the trial has started and then restrict regimens to those mentioned in section on ARVs or\n\n   • The participant is ARV experienced (has been on ARV´s a minimum of 5 months), AND: ARV treatment is compliant to, or can be modified as described in the section on Antiretroviral Therapy\n6. The participant has a known intolerance to any of the study drugs or concomitant disorders or conditions for which study drugs or standard TB treatment are contraindicated.\n7. The participant has a history of, or current evidence of clinically relevant cardiovascular metabolic, gastrointestinal, neurological, hepato-biliary, renal, psychiatric or endocrine diseases, malignancy, or any other condition that will influence treatment response, study adherence or survival in the judgement of the investigator, especially:\n\n   a. Neuropathy, or significant psychiatric disorder like depression or schizophrenia; especially if treatment for those has ever been required or is anticipated to be required b. Evidence of clinically significant extra-pulmonary TB (e.g. miliary TB, TB meningitis, but not limited lymph node involvement) c. Serious lung conditions other than TB, or significant respiratory impairment in the discretion of the investigator d. Uncontrolled diabetes mellitus or diabetes mellitus receiving\u002Frequiring treatment with metformin or sulfonylureas e. Cardiovascular disease such as myocardial infarction, heart failure, coronary heart disease, arrhythmia, tachyarrhythmia, or pulmonary hypertension f. Uncontrolled arterial hypertension (systolic blood pressure ≥150 mmHg and\u002For diastolic blood pressure of ≥95 mmHg on two occasions during screening. An attempt at antihypertensive treatment during the screening period is permitted).\n\n   g. Long QT syndrome or family history of long QT syndrome or family history of sudden death of unknown or cardiac-related cause h. Alcohol, regular opiate, or other drug abuse that is sufficient to significantly compromise the safety or cooperation of the participant, that includes substances prohibited by the protocol or has led to significant organ damage at the discretion of the investigator; AND\u002FOR any abuse of methamphetamine.\n\n   i. History of optic neuropathy j. Vitiligo\n8. Any of the following laboratory findings at screening:\n\n   a. Serum amino aspartate transferase (AST) and\u002For alanine aminotransferase (ALT) \\>3x the upper limit of normal (ULN), b. Serum alkaline phosphatase or y-glutamyl transferase \\> 2.5x the ULN, c. Serum total bilirubin level \\>1.5x the ULN d. Estimated creatinine clearance -eCrCl (using the CKD-EPI 2021 creatinine formula):\n\n   \\- Stage 1: Lower than 30 ml\u002Fmin)\n\n   \\- Stage 2: Lower than 30ml\u002Fmin or lower than 60 ml\u002Fmin in participants living with HIV\n\n   \\- Stage 3: Lower than 80ml\u002Fmin e. Proteins in urine dipstick \\>=2+ f. Haemoglobin level \\\u003C7.0 g\u002Fdl g. Platelet count \\\u003C50,000\u002Fmm3, h. Serum potassium below 3 mmol\u002Fl, persisting after correction.\n9. ECG findings in the screening ECG: (one or more):\n\n   1. QTcF of \\>450 milliseconds\n   2. Atrioventricular (AV) block with PR interval \\> 200 milliseconds\n   3. QRS complex \\> 120 milliseconds\n   4. Any other changes in the ECG that are clinically relevant as per discretion of the investigator\n10. Restricted medication:\n\n    1. Treatment with any other investigational drug within 2 month prior to enrolment or enrolment into other clinical (intervention) trials during participation.\n    2. Previous anti-TB treatment with drugs active against MTB within the last 3 months prior to screening.\n    3. Unable or unwilling to abide by the requirements regarding restricted medication or have taken restricted medication. Restricted medication includes the following drug classes, with relevant timing of intake, and possible exceptions. Exceptions may be permissible after discussion with the sponsor medical expert.","18 Years","65 Years",{"count":59,"type":21},390,[61],"PHASE2","This is a phase 2B\u002FC, open label platform study that will compare the efficacy, safety of experimental regimens with a standard control regimen in participants with newly diagnosed, drug sensitive pulmonary tuberculosis.\n\nIn stage 1, participants will be randomly allocated to the control or one of the 2 rifampicin-containing experimental regimens in the ratio 1:1:1.\n\nIn stage 2, the experimental arm 4 containing BTZ-043 will be added. The allocation ratio will be changed to co-enrol the remaining participants in arms 1- 3 simultaneously with arm 4 in a ratio of 1:1:1:2. When arms 1-2 are fully enrolled and arm 4 is not, further participants will be randomized 1:1 to control and experimental arm 4. Not all countries will participate in stage 2.\n\nIn stage 3, participants will be allocated in parallel to control arm treatment (now designated arm 7) or the experimental arms 5 and 6, favouring arm 5, 2:1:1 over arms 6 and control. This stage will start after completion of recruitment in the stages 1 and 2. Enrolment of participants into arm 5 will proceed following review of data from the ENABLE\u002FUNITE-03 (NCT06748937), non-clinical safety data and after endorsement by the DSMB. Thus, arm 5 recruitment might start after arms 6 and 7, which may require an increase in the control arm sample size to ensure controls are recruited concomitantly.",[64,65],"Pulmonary Tuberculosis","Other Specified Pulmonary Tuberculosis",[67,68,69,70,71,72,73,74,75],"Tuberculosis, Pulmonary","Tuberculosis","Antitubercular Agents","Safety","Tolerability","Pharmacokinetics (PK)","Moxifloxacin","BTZ-043","Rifampicin","2025-10-01",{"date":78,"type":40},"2025-10-07",{"date":80,"type":40},"2023-04-14",{"date":82,"type":21},"2027-12-30",{"name":84,"class":47},"Michael Hoelscher",10,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":94,"maxAge":56,"enrollmentInfo":95,"targetDuration":97,"studyType":98,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100347437","hospital-based-registry-of-childhood-cancer-in-pediatric-oncology-units-in-french-speaking-africa-100347437","NCT03803735","Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa","French African Pediatric Oncology Registry","RFAOP","Inclusion Criteria:\n\n1. Any child presenting at any one of the participating units for treatment\n2. Any child with any type of cancer\n3. Any child or adolescent less than 18 years of age.\n\nExclusion Criteria:\n\n1. No cancer found\n2. Age greater than 18 years -","1 Day",{"count":96,"type":21},10000,"12 Months","OBSERVATIONAL","The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group. This data will help to plan and provide correct pediatric oncology treatment and care for this population.\n\nCollecting the data will give much needed information on numbers, stage, treatment and outcome. The register will give data for local and national health authorities in planning pediatric cancer programs.",[101],"Pediatric Cancer","2025-09-29",{"date":104,"type":40},"2025-10-03",{"date":106,"type":40},"2016-01-01",{"date":108,"type":21},"2030-12",{"name":110,"class":47},"French Africa Pediatric Oncology Group",14,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":143},"100496929","phase-2-platform-study-to-evaluate-the-efficacy-and-safety-of-anti-malarial-agents-in-patients-with-uncomplicated-plasmodium-falciparum-malaria-100496929","NCT05750628","Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria","A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and\u002For Combination Therapy IN Patients With Uncomplicated Plasmodium Falciparum Malaria","PLATINUM","Inclusion Criteria:\n\n1. Male and female patients ≥18 years of age for Part A, ≥12 years of age for Part B and 2 to \\\u003C12 years of age for Part C at screening.\n2. Patients must have acute uncomplicated P. falciparum malaria mono infection at screening confirmed by a parasite count between 5,000 to 150,000 asexual parasite count\u002Fμl of blood for P. falciparum for Part A and between 1,000 to 150,000 asexual parasite count\u002Fμl of blood for Parts B and C.\n3. Patients in Part A must weigh between 40 kg and 90 kg. Patients in Part B must weigh between 35 kg and 90 kg at screening. Patients in Part C must weigh at least 10 kg at screening.\n4. Axillary temperature ≥ 37.5ºC or oral\u002Ftympanic\u002Frectal temperature ≥ 38.0ºC; or history of fever during the previous 24 hours.\n\nExclusion Criteria:\n\n1. Patients with signs and symptoms of severe\u002Fcomplicated malaria at screening or mixed Plasmodium infection (i.e., infection with more than one malaria species) at screening\n2. Moderate to severe anemia, chronic hemoglobinopathy (Hemoglobin level \\\u003C 8 g\u002FdL), or known chronic underlying disease such as sickle cell disease at screening\n3. Known clinically significant liver disease (e.g., chronic hepatitis, liver cirrhosis (compensated or decompensated), history of hepatitis B or C, hepatitis A or B vaccination in the last 3 months, known gallbladder or bile duct disease, acute or chronic pancreatitis. Clinical or laboratory evidence of any of the following at screening:\n\n   * AST\u002FALT \\> 3 x the upper limit of normal range (ULN), regardless of the level of total bilirubin\n   * AST\u002FALT \\> 1.5 and ≤ 2 x ULN and total bilirubin is \\> ULN\n   * Total bilirubin \\> 2 x ULN, regardless of the level of AST\u002FALT\n4. Any known\u002Fsuspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection at screening.\n5. Pregnant or nursing (lactating) women, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using methods of effective contraception, and sexually active patients not willing to practice effective contraception.\n6. History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study such as:\n\n   * Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker\n   * History of familial long QT syndrome or known family history of Torsades de Pointe.\n   * Resting heart rate (physical exam or 12 lead ECG) \\\u003C 50 bpm\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","2 Years","100 Years",{"count":123,"type":21},327,[61],"Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria",[127],"Uncomplicated Plasmodium Falciparum Malaria",[129,130,131,132,118],"malaria","uncomplicated malaria","Plasmodium falciparum","platform study","2025-07-29",{"date":135,"type":40},"2025-07-30",{"date":137,"type":40},"2024-01-23",{"date":139,"type":21},"2026-06-23",{"name":141,"class":142},"Novartis Pharmaceuticals","INDUSTRY",12,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":171},"100509315","phase-1-a-study-to-determine-safety-tolerability-and-pharmacokinetics-of-different-orally-administered-regimens-of-the-combination-zy19489-ferroquine-in-adult-asymptomatic-plasmodium-falciparum-carriers-100509315","NCT05911828","A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers","Phase Ib, Single-center, Randomized, Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers","ZYFER-1","Inclusion Criteria:\n\n\\- 1. Male and female (non-pregnant, non-lactating) subjects aged between 18 and 55 years old 2. Participant's body weight ≥ 45 kg 3. Evidence of asymptomatic infection with Plasmodium falciparum mono-infection on microscopy with parasite density between 20\u002FµL and 5000\u002FµL.\n\n4\\. Participants should agree to not donate blood from enrolment in the study until end of the follow-up period 5. Ability to swallow oral medication 6. Evidence of written informed consent personally signed and dated by the participant.\n\nSigned informed consent obtained prior to participation in the study. In case of participant unable to read and write or otherwise incapable of signing an informed consent, an impartial witnessed consent shall be obtained. Participants who are willing to and are able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* 1\\. Mixed Plasmodium infection as judged by microscopy. 2. Presence of clinically significant infectious disease or fever (e.g. Body temperature ≥38°C or 100.4°F) within the 14 days prior to enrollment.\n\n  3\\. History of alcohol or drug abuse or positive urine alcohol test or urine drug test.\n\n  4\\. Consumption of beverages or food containing xanthine bases including chocolate, coffee etc. from 48 hours prior to enrollment.\n\n  5\\. Known allergy to the study drugs and to the rescue medications (artemisinin derivatives, lumefantrine) as well as their excipients.\n\n  6\\. History of having received any antimalarial treatment (alone or in combination) during the following periods before screening:\n  1. Piperaquine, mefloquine, naphthoquine or sulfadoxine-pyrimethamine within 6 weeks prior to screening.\n  2. Amodiaquine, chloroquine within 4 weeks prior to screening.\n  3. Any artemisinin derivative (artesunate, artemether or dihydroartemisinin), quinine, lumefantrine or any other anti-malarial treatment or antibiotic with antimalarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones and azithromycin) within 14 days prior to screening.\n\n     7\\. Laboratory parameters outside normal range or with clinically relevant abnormalities as per investigator's judgment.\n\n     8\\. Electrolyte levels outside normal range 9. Hematology, clinical chemistry or urinalysis results at screening that were outside of clinically acceptable laboratory ranges and were considered clinically significant by the Investigator.\n\n     10\\. GFR\\\u003C60 ml\u002Fmin. 11. Previous participation in any malaria vaccine study or received malaria vaccine in any other circumstance within 3 months of screening.\n\n     12\\. Participation in other clinical studies within 90 days before screening. 13. Pregnant or nursing (lactating) women. 14. Sexually active participants not willing to take effective contraception measures from enrolment until the last study visit: For female participants, combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner.\n\n     15\\. All male participants not willing to use either true abstinence, barrier method or with their sexual partner, the use of effective means of contraception from enrolment and until the last study visit.\n\n     16\\. Participant who the investigator considers at particular risk of receiving an anti-malarial or of participating in the study.","55 Years",{"count":154,"type":21},36,[156],"PHASE1","Malaria is caused by protozoan parasites of the genus Plasmodium and it is the most important parasitic disease in terms of mortality and morbidity. Estimates of 247 million malaria cases and 619.000 deaths worldwide were reported by WHO for the year 2021 (1). Plasmodium falciparum can lead to severe malaria and accounts for 90% of malaria deaths that mainly occur in children below the age of 5 years in Sub-Saharan Africa.\n\nA simplified treatment regimen, ideally a single-day cure (or at most 2-day dosing regimen), of uncomplicated malaria due to P. falciparum would be the magic in the antimalarial armamentarium. Improving treatment adherence is one of the key factors in reducing mortality and morbidity and also the transmission of malaria, and such a regimen would substantially increase adherence. To find a new non-artemisinin combination therapy with a shorter regimen, ideally, a single-dose cure, with low resistance potential would be the aim. The two compounds tested here are ZY19489, a triaminopyrimidine, and ferroquine (FQ), a next-generation 4-aminoquinoline. Both compounds show unique features in terms of long half-life, and activity against current drug-resistant strains.\n\nTherefore, the main goal of this clinical trial is to assess the safety of the ZY19489-FQ combination given as a 1- or 2-day dose regimen.",[159,160,161],"Uncomplicated Malaria","Asymptomatic Condition","Falciparum Malaria","2024-09-27",{"date":164,"type":40},"2024-10-01",{"date":166,"type":40},"2024-08-30",{"date":168,"type":21},"2025-05-30",{"name":170,"class":142},"Zydus Lifesciences Limited",1,""]